DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for nervous system benign neoplasm — screening already-approved drugs against its 35-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNervous system benign neoplasm maps to a 35-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for nervous system benign neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ArfGAP with FG repeats 1 (AGFG1) — AGFG1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2OLM · 1.48 Å · ligand Unknown ligand (UNL). Experimental structure, not a prediction.
What the evidence adds up to
These three abstracts do not report any drug trial or treatment outcome. The 1997 paper argues that some central nervous system lesions are overtreated because they are misdiagnosed as aggressive neoplasms when they are actually low-grade or nonneoplastic; it offers no numbers, no survival data, and no drug. The 2009 abstract describes paraneoplastic syndromes of the nervous system as immune-mediated neurological disorders that often precede a cancer diagnosis; it mentions no drug, no response rate, and no sample size. The 2005 abstract states that apart from a small percentage of benign tumours (most meningiomas and pituitary adenomas), central nervous system neoplasms are progressive and not curable, and that recurrence is virtually inevitable after surgery, radiotherapy, or sometimes chemotherapy.
No evidence for any drug repurposing in benign nervous system neoplasms appears in these abstracts. There is no mention of a specific drug, no response rate, no survival benefit, and no controlled comparison. The 2005 paper explicitly says that for the vast majority of CNS neoplasms, cure cannot be promised.
What is missing is any trial data, any drug name, any patient stratification, and any funding for a repurposing study in benign nervous system neoplasms. Without abstracts that report drug exposure and outcomes, no evidence summary can be written.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1997 · 21 citations · open access
An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions
AbstractIn spite of evidence to the contrary, some low grade central nervous system tumors and even nonneoplastic lesions can be misconstrued as aggressive neoplasms and treated accordingly. However, when these lesions are reviewed in their full clinical, radiologic, and pathologic context, features often are present suggesting that a low grade neoplasm or nonneoplastic lesion is present. This article reviews these alerting features.
Cerebral spinal fluid abnormalities in patients with paraneoplastic syndromes of the nervous system
AbstractParaneoplastic syndromes of the nervous system (PNS) are neurological disorders associated with cancer, not caused by metastases or indirect effects such as complications of therapy. Although PNS are uncommon, they are an important as they frequently cause significant neurological morbidity. As PNS often antedate the diagnosis of the underlying cancer, early diagnosis is important as this offers the best chance of a favourable outcome for the cancer, as well as for the neurological disorder.1 There is growing consensus that most PNS are caused by an immune response generated against antigens shared by both the cancer cells and components of …
Cambridge University Press eBooks · 2005 · 0 citations
Cerebral neoplasms
AbstractApart from a small percentage of benign tumours (most meningiomas and pituitary adenomas) neoplasms of the central nervous system are progressive and not curable. Initial management with surgery or radiotherapy (and sometimes chemotherapy) will often lead to a resolution of symptoms for a variable period, but cure cannot be promised, and a recurrence of tumour is virtually inevitable.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
